Asthma And COPD MarketSize and Trends

The Global Asthma And COPD Market is estimated to be valued at US$ 35.2 Bn in 2023 and is expected to exhibit a CAGR of 4.9% during the forecast period (2023-2030).

Figure 1. Global Asthma And COPD Market Share (%), by Drug Type, 2023

Global Asthma And COPD Market– Driver

Increasing research & development activities in the asthma and COPD field

The growing research & development activities a major factor leading to the high demand for asthma and COPD drug treatments. For instance, on May 23, 2023, a clinical trial conducted by AstraZeneca, a global, science-led biopharmaceutical business, showed that initiating fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate) within 30 days of a qualifying moderate or severe exacerbation in patients with COPD (chronic obstructive pulmonary disease), is associated with a decreased risk of future exacerbations by 24%.

Expansion of manufacturing facilities regarding asthma and COPD drug treatments

The expansion of production & manufacturing facilities to produce newer drug therapies can drive the growth of the global asthma and COPD market. For instance, in October 2021, Honeywell, a publicly traded, multinational conglomerate corporation, announced the opening of a plant in Louisinia, U.S., that is the company’s first large-scale manufacturing site for Solstice Air, a near-zero global-warming-potential (GWP) medical propellant for use in respiratory inhalers.

Figure 2. Global Asthma And COPD Market Value (%), by Region, 2023

Global Asthma And COPD Market Segmentation:

The global asthama and COPD market report is segmented into drug type, disease type, distribution channel, and region.

By Drug Type, the market is segmented into bronchodilators, anti-inflammatories and combination therapies. Out of which, the bronchodilators segment is expected to hold a dominant position in the global asthama and COPD market during the forecast period and this is attributed to its targeted drug delivery.

By Disease Type, the market is segmented into asthma and COPD. Out of which, the asthma segment is expected to hold a dominant position in the global asthama and COPD market during the forecast period and this is attributed to the increasing prevalence of the disease globally.

By Distribution Channel, the market is segmented hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacy segment is expected to dominate the market over the forecast period and this is attributed to the increasing hospitalizations caused by respiratory disorders all over the world.

By Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Out of which, the North America segment is expected to dominate the market over the forecast period and this is attributed to the increased research & development activities in the region.

Among all the segmentations, the disease type segment has the highest potential due to the increasing prevalence of the disease. For instance, according to the data shared on November 23, 2020, by Cleaveland Clinic, a non-profit system of public hospitals, in the U.S., as of 2020, about 25 million people were suffering from asthma. Out of which, approximately 60% had asthma that is caused by allergies.

Global Asthma And COPD Market Cross Sectional Analysis:

Among drug type, bronchodilators segment is expected to show maximum growth in Asia Pacific region due to the increased product launches regarding asthma and COPD drug treatments. For instance, on January 3, 2023, Lupin, an India-based pharmaceuticals firm, announced that it had launched a fixed-dose triple drug combination of 3 bronchodilators- Indacaterol, Glycopyrronium, and Mometasone, for managing asthma.

Global Asthma And COPD Market: Key Trends

The increasing drug discovery and drug development activities provide lucrative opportunities for the growth of the asthma and COPD market. In July 2022, AstraZeneca, a biopharmaceutical company’s drug- Tezspire (tezepelumab) was recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma. Tezspire acts at the top of the inflammatory cascade by blocking thymic stromal lymphopoietin (TSLP), an epithelial cytokine.Tezspire consistently and significantly reduced asthma exacerbations across Phase II and III clinical trials, which included a broad population of severe asthma patients.

The rising avent of partnerships, mergers, and agreement scenarios can provide lucrative opportunities for the growth of the global asthma and COPD market. For instance, in July 2022, Knopp Biosciences LLC, a privately held company managing a portfolio of equity securities and future product royalties, and Population Health Partners, an investment company focused on innovative therapeutics with the potential to transform health outcomes for populations, announced the establishment of Areteia Therapeutics, a new clinical-stage medical company focused on putting asthma patients in better control of its disease with the first potential oral therapy for eosinophilic asthma.